📣 VC round data is live. Check it out!

Inhalation Sciences SWE Valuation Multiples

Discover revenue and EBITDA valuation multiples for Inhalation Sciences SWE and similar public comparables like Strata Skin Sciences, Brain Scientific, Profusa, Epigenomics and more.

Inhalation Sciences SWE Overview

About Inhalation Sciences SWE

Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.


Founded

2004

HQ

Sweden

Employees

9

Financials (FY)

Revenue: $327K
EBITDA: ($1M)

EV

$846K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Inhalation Sciences SWE Financials

Inhalation Sciences SWE reported last fiscal year revenue of $327K and negative EBITDA of ($1M).

In the same fiscal year, Inhalation Sciences SWE generated $278K in gross profit, ($1M) in EBITDA losses, and had net loss of ($1M).


Inhalation Sciences SWE P&L

In the most recent fiscal year, Inhalation Sciences SWE reported revenue of $327K and EBITDA of ($1M).

Inhalation Sciences SWE is unprofitable as of last fiscal year, with gross margin of 85%, EBITDA margin of (319%), and net margin of (334%).

See analyst estimates for Inhalation Sciences SWE
Last FY202320242025202620272028
Revenue$327K$2M$1M$327K
Gross Profit$278K$2M$1M$278K
Gross Margin85%80%92%85%
EBITDA($1M)($283K)($424K)($1M)
EBITDA Margin(319%)(15%)(36%)(319%)
EBIT Margin(334%)(21%)(46%)(334%)
Net Profit($1M)($510K)($553K)($1M)
Net Margin(334%)(27%)(47%)(334%)

Financial data powered by Morningstar, Inc.

Inhalation Sciences SWE Stock Performance

Inhalation Sciences SWE has current market cap of $1M, and enterprise value of $846K.

Market Cap Evolution


Inhalation Sciences SWE's stock price is $0.02.

Inhalation Sciences SWE share price decreased by 7.8% in the last 30 days, and by 52.3% in the last year.

Inhalation Sciences SWE has an EPS (earnings per share) of $-0.02.

See more trading valuation data for Inhalation Sciences SWE
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$846K$1M-7.1%-7.8%-18.1%-52.3%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Inhalation Sciences SWE Valuation Multiples

Inhalation Sciences SWE trades at 2.6x EV/Revenue multiple, and (0.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Inhalation Sciences SWE

Inhalation Sciences SWE Financial Valuation Multiples

As of June 4, 2026, Inhalation Sciences SWE has market cap of $1M and EV of $846K.

Inhalation Sciences SWE has a P/E ratio of (1.1x).

Last FY202320242025202620272028
EV/Revenue2.6x0.4x0.7x2.6x
EV/EBITDA(0.8x)(3.0x)(2.0x)(0.8x)
EV/EBIT(0.8x)(2.1x)(1.6x)(0.8x)
EV/Gross Profit3.0x0.6x0.8x3.0x
P/E(1.1x)(2.4x)(2.2x)(1.1x)
EV/FCF(0.7x)(2.1x)(2.7x)(0.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Inhalation Sciences SWE Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Inhalation Sciences SWE Margins & Growth Rates

In the most recent fiscal year, Inhalation Sciences SWE reported gross margin of 85%, EBITDA margin of (319%), and net margin of (334%).

See estimated margins and future growth rates for Inhalation Sciences SWE

Inhalation Sciences SWE Margins

Last FY20242025202720282029
Gross Margin85%92%85%
EBITDA Margin(319%)(36%)(319%)
EBIT Margin(334%)(46%)(334%)
Net Margin(334%)(47%)(334%)
FCF Margin(355%)(27%)(355%)

Inhalation Sciences SWE Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(37%)(72%)
Gross Profit Growth(28%)(74%)
EBITDA Growth50%146%
EBIT Growth35%100%
Net Profit Growth8%97%
FCF Growth(22%)267%

Data powered by FactSet, Inc. and Morningstar, Inc.

Inhalation Sciences SWE Operational KPIs

Inhalation Sciences SWE's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for Inhalation Sciences SWE
Last FY202320242025202620272028
Revenue per Employee$0.0M---
Opex per Employee$0.2M---
S&M Expenses to Revenue139%35%45%139%
G&A Expenses to Revenue144%28%37%144%
R&D Expenses to Revenue137%41%61%137%
Opex to Revenue419%101%137%419%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Inhalation Sciences SWE Competitors

Inhalation Sciences SWE competitors include Strata Skin Sciences, Brain Scientific, Profusa, Epigenomics, Nuwellis, Longevity Health Holdings, SensoDetect, Invent Medic Sweden, BBS-Bioactive Bone and EvokAI.

Most Inhalation Sciences SWE public comparables operate across Medical Devices and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Strata Skin Sciences----
Brain Scientific----
Profusa--(0.4x)-
Epigenomics488.9x-(37.4x)-
Nuwellis(0.0x)(0.0x)0.0x-
Longevity Health Holdings----
SensoDetect2.9x-(0.8x)-
Invent Medic Sweden2.2x-(3.4x)-

This data is available for Pro users. Sign up to see all Inhalation Sciences SWE competitors and their valuation data.

Start Free Trial

Inhalation Sciences SWE VC Funding History

Before going public, Inhalation Sciences SWE raised $1M in total equity funding, across 2 rounds.


Inhalation Sciences SWE Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-17Pre-seed-$400K--
Dec-16Pre-seedSciety$600K--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Inhalation Sciences SWE

When was Inhalation Sciences SWE founded?Inhalation Sciences SWE was founded in 2004.
Where is Inhalation Sciences SWE headquartered?Inhalation Sciences SWE is headquartered in Sweden.
How many employees does Inhalation Sciences SWE have?As of today, Inhalation Sciences SWE has over 9 employees.
Is Inhalation Sciences SWE publicly listed?Yes, Inhalation Sciences SWE is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Inhalation Sciences SWE?Inhalation Sciences SWE trades under ISAB ticker.
When did Inhalation Sciences SWE go public?Inhalation Sciences SWE went public in 2017.
Who are competitors of Inhalation Sciences SWE?Inhalation Sciences SWE main competitors include Strata Skin Sciences, Brain Scientific, Profusa, Epigenomics, Nuwellis, Longevity Health Holdings, SensoDetect, Invent Medic Sweden, BBS-Bioactive Bone, EvokAI.
What is the current market cap of Inhalation Sciences SWE?Inhalation Sciences SWE's current market cap is $1M.
What is the current revenue of Inhalation Sciences SWE?Inhalation Sciences SWE's last fiscal year revenue is $327K.
What is the current EV/Revenue multiple of Inhalation Sciences SWE?Current revenue multiple of Inhalation Sciences SWE is 2.6x.
Is Inhalation Sciences SWE profitable?No, Inhalation Sciences SWE is not profitable.
How many companies Inhalation Sciences SWE has acquired to date?Inhalation Sciences SWE hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Inhalation Sciences SWE has invested to date?Inhalation Sciences SWE hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Inhalation Sciences SWE

Lists including Inhalation Sciences SWE

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial